SRPT241129C145000
- 0.25
- 0.000.00%
Sarepta Therapeutics Newsroom
Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs
Sector Update: Health Care
Top Midday Gainers
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics' Strategic Partnership With Arrowhead Signals Strong Growth Prospects: A Buy Recommendation
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Arrowhead Stock Soars on $825M Sarepta Therapeutics Deal
Oppenheimer Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $215
Sarepta Therapeutics Announces Leadership Change and Equity Deal
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Express News | Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS
Express News | Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board
Express News | Sarepta Therapeutics Inc - Approves $500 Million Share Repurchase Authorization
Express News | Sarepta Therapeutics Inc - Arrowhead to Receive $500 Million Upfront and $325 Million Equity Investment
Express News | Sarepta Therapeutics Inc - Obtains Exclusive Licenses to Seven Programs
Express News | Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement With Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical Sirna Programs
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Analyst Expectations For Sarepta Therapeutics's Future